Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Intensity-based volumetric registration of magnetic resonance images and whole-mount sections of the prostate.

Losnegård A, Reisæter L, Halvorsen OJ, Beisland C, Castilho A, Muren LP, Rørvik J, Lundervold A.

Comput Med Imaging Graph. 2018 Jan;63:24-30. doi: 10.1016/j.compmedimag.2017.12.002. Epub 2017 Dec 15.

PMID:
29276002
2.

Optimising preoperative risk stratification tools for prostate cancer using mpMRI.

Reisæter LAR, Fütterer JJ, Losnegård A, Nygård Y, Monssen J, Gravdal K, Halvorsen OJ, Akslen LA, Biermann M, Haukaas S, Rørvik J, Beisland C.

Eur Radiol. 2018 Mar;28(3):1016-1026. doi: 10.1007/s00330-017-5031-5. Epub 2017 Oct 6.

3.
4.
5.

Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort.

Nygård Y, Haukaas SA, Eide GE, Halvorsen OJ, Gravdal K, Frugård J, Akslen LA, Beisland C.

Scand J Urol. 2015 Feb;49(1):8-15. doi: 10.3109/21681805.2014.949841. Epub 2014 Aug 20.

PMID:
25141128
6.

1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy.

Reisæter LA, Fütterer JJ, Halvorsen OJ, Nygård Y, Biermann M, Andersen E, Gravdal K, Haukaas S, Monssen JA, Huisman HJ, Akslen LA, Beisland C, Rørvik J.

Acta Radiol. 2015 Apr;56(4):500-11. doi: 10.1177/0284185114531754. Epub 2014 May 12.

PMID:
24819231
7.

GRK3 is essential for metastatic cells and promotes prostate tumor progression.

Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, Signoretti S, Hu Y, Boyce FM, Gravdal K, Halvorsen OJ, Nalwoga H, Akslen LA, Harlow E, Watnick RS.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1521-6. doi: 10.1073/pnas.1320638111. Epub 2014 Jan 13.

8.

A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting.

Nygård Y, Haukaas SA, Halvorsen OJ, Gravdal K, Frugård J, Akslen LA, Beisland C.

BJU Int. 2014 May;113(5b):E90-7. doi: 10.1111/bju.12401. Epub 2013 Nov 27.

9.

Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1.

Catena R, Bhattacharya N, El Rayes T, Wang S, Choi H, Gao D, Ryu S, Joshi N, Bielenberg D, Lee SB, Haukaas SA, Gravdal K, Halvorsen OJ, Akslen LA, Watnick RS, Mittal V.

Cancer Discov. 2013 May;3(5):578-89. doi: 10.1158/2159-8290.CD-12-0476. Epub 2013 Apr 30.

10.

Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers.

Nygård Y, Haukaas SA, Waage JE, Halvorsen OJ, Gravdal K, Frugård J, Akslen LA, Beisland C.

Scand J Urol. 2013 Jun;47(3):211-6. doi: 10.3109/00365599.2012.727859. Epub 2012 Oct 4.

PMID:
23035756
11.

Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007.

Kvåle R, Møller B, Angelsen A, Dahl O, Fosså SD, Halvorsen OJ, Hoem L, Solberg A, Wahlqvist R, Bray F.

Cancer Epidemiol. 2010 Aug;34(4):359-67. doi: 10.1016/j.canep.2010.04.017. Epub 2010 Jun 2.

PMID:
20627840
12.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.

Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, Budäus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.

APMIS. 2009 Aug;117(8):575-82. doi: 10.1111/j.1600-0463.2009.02517.x.

PMID:
19664128
13.

Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1.

Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas SA, Aamodt K, Yoo S, Akslen LA, Watnick RS.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12115-20. doi: 10.1073/pnas.0903120106. Epub 2009 Jul 6. Erratum in: Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15513.

14.

Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy.

Karlsdottir A, Muren LP, Wentzel-Larsen T, Johannessen DC, Haukaas SA, Halvorsen OJ, Dahl O.

Acta Oncol. 2009;48(6):874-81. doi: 10.1080/02841860902974159.

PMID:
19488886
15.

Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.

Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA.

Cancer Res. 2009 Jun 1;69(11):4708-15. doi: 10.1158/0008-5472.CAN-08-4417. Erratum in: Cancer Res. 2009 Jul 15;69(14):6005.

16.

Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH.

PLoS One. 2009;4(3):e4687. doi: 10.1371/journal.pone.0004687. Epub 2009 Mar 5.

17.

Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.

Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, Busch C, Kyrdalen AE, Svindland A, Viset T, Halvorsen OJ.

BJU Int. 2009 Jun;103(12):1647-54. doi: 10.1111/j.1464-410X.2008.08255.x. Epub 2008 Dec 22.

18.
19.

WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.

Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA.

Clin Cancer Res. 2008 Mar 1;14(5):1397-406. doi: 10.1158/1078-0432.CCR-07-1535.

21.

Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.

Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, Steen VM, Jonassen I, Kalland KH.

Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.

PMID:
17449007
22.

Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.

Halvorsen OJ, Rostad K, Øyan AM, Puntervoll H, Bø TH, Stordrange L, Olsen S, Haukaas SA, Hood L, Jonassen I, Kalland KH, Akslen LA.

Clin Cancer Res. 2007 Feb 1;13(3):892-7.

23.

ERG upregulation and related ETS transcription factors in prostate cancer.

Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bø TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, Kalland KH.

Int J Oncol. 2007 Jan;30(1):19-32.

PMID:
17143509
24.

A concomitant tumour boost in bladder irradiation: patient suitability and the potential of intensity-modulated radiotherapy.

Muren LP, Redpath AT, McLaren D, Rørvik J, Halvorsen OJ, Høstmark J, Bakke A, Thwaites D, Dahl O.

Radiother Oncol. 2006 Jul;80(1):98-105. Epub 2006 Jul 28.

PMID:
16876274
25.

Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer.

Karlsdottir A, Muren PL, Wentzel-Larsen T, Johannessen DC, Bakke A, Ogreid P, Halvorsen OJ, Dahl O.

Acta Oncol. 2006;45(4):454-62.

PMID:
16760182
27.

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA.

J Clin Oncol. 2006 Jan 10;24(2):268-73. Epub 2005 Dec 5.

PMID:
16330673
28.

Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer.

Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA.

Virchows Arch. 2006 Jan;448(1):68-74. Epub 2005 Oct 12.

PMID:
16220297
29.

Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.

Halvorsen OJ, Oyan AM, Bø TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH.

Int J Oncol. 2005 Feb;26(2):329-36.

PMID:
15645116
30.

Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.

Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA.

J Urol. 2005 Feb;173(2):425-8.

PMID:
15643193
31.
33.

Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.

Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, Bégin LR, Foulkes WD, Akslen LA.

Cancer Res. 2002 Dec 1;62(23):6808-11.

34.

Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy.

Halvorsen OJ, Haukaas S, Høisaeter PA, Akslen LA.

Anticancer Res. 2001 Nov-Dec;21(6A):4071-6.

PMID:
11911294
35.

Neonatal lethal dwarfism with distinct skeletal malformations--a separate entity?

Rosendahl K, Maurseth K, Olsen ØE, Halvorsen OJ, Gjelland K, Engebretsen L.

Pediatr Radiol. 2001 Sep;31(9):663-8. Review.

PMID:
11512011
36.

Independent prognostic importance of microvessel density in clinically localized prostate cancer.

Halvorsen OJ, Haukaas S, Høisaeter PA, Akslen LA.

Anticancer Res. 2000 Sep-Oct;20(5C):3791-9.

PMID:
11268456
37.

Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.

Halvorsen OJ, Høstmark J, Haukaas S, Høisaeter PA, Akslen LA.

Cancer. 2000 Jan 15;88(2):416-24.

PMID:
10640976
38.

Cushing's syndrome in prostate cancer. An aggressive course of prostatic malignancy.

Haukaas SA, Halvorsen OJ, Nygaard SJ, Paus E.

Urol Int. 1999;63(2):126-9.

PMID:
10592502
39.

Use of pelvic surface coil MR imaging for assessment of clinically localized prostate cancer with histopathological correlation.

Rørvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S.

Clin Radiol. 1999 Mar;54(3):164-9.

PMID:
10201864
40.

MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy.

Rørvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S.

Eur Radiol. 1999;9(1):29-34.

PMID:
9933375
41.

Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer.

Rørvik J, Halvorsen OJ, Albrektsen G, Haukaas S.

Scand J Urol Nephrol. 1998 Apr;32(2):116-9.

PMID:
9606783
42.

Tumour size measured by transrectal ultrasonography in the staging of prostate cancer before radical prostatectomy.

Rørvik J, Albrektsen G, Halvorsen OJ, Haukaas S.

Br J Urol. 1997 Aug;80(2):269-73.

PMID:
9284201
43.

When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?

Haukaas S, Roervik J, Halvorsen OJ, Foelling M.

Br J Urol. 1997 May;79(5):770-6.

PMID:
9158517
44.

Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands.

Halvorsen OJ, Haukaas S, Høisæter PÅ, Akslen LA.

Urol Oncol. 1997 Mar-Apr;3(2):59-66.

PMID:
21227061
45.

Transcutaneous abdominal ultrasonography in the staging of lung cancer.

Bakke PS, Taule M, Lillo E, Melgren G, Magnussen IJ, Halvorsen OJ.

Thorax. 1997 Mar;52(3):276-80.

46.

Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy.

Rørvik J, Halvorsen OJ, Servoll E, Haukaas S.

Br J Urol. 1994 Jan;73(1):65-9.

PMID:
8298901
47.

Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.

Mørkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A, Laerum OD.

Anticancer Res. 1993 May-Jun;13(3):571-8.

PMID:
8391242
48.

Inability of refined CT to assess local extent of prostatic cancer.

Rørvik J, Halvorsen OJ, Espeland A, Haukaas S.

Acta Radiol. 1993 Jan;34(1):39-42.

PMID:
8427747
49.

Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer.

Mørkve O, Halvorsen OJ, Stangeland L, Gulsvik A, Laerum OD.

Int J Cancer. 1992 Dec 2;52(6):851-5.

PMID:
1334053
50.

Transrectal ultrasonography in the staging of localized prostatic carcinoma. A pilot study.

Rørvik J, Servoll E, Halvorsen OJ.

Scand J Urol Nephrol. 1992;26(1):15-9.

PMID:
1631502

Supplemental Content

Loading ...
Support Center